EYPT earnings

WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/i8pzi8wg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A w

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2025 to report its third quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/fgkir3sg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharm

– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO on track for readout in mid-2026 with LUCIA topline data to closely follow – – Northbridge, MA commercial manufacturing facility on line with DURAVYU registration batches underway – – $256 million of cash, cash equivalents and marketable securities as of June 30, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials – WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuti

WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register-conf.media-server.com/register/BI2f02d8b4966b40da83f2ef4135b2ba78. A live audio webcast of the event can be accessed via the Investors section of the

– Enrollment continues to exceed expectations in DURAVYU™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as of March 31, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials expected in 2026 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious

WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register-conf.media-server.com/register/BI0695874f15d442e59e2fb362d4491cac. A live audio webcast of the event can be accessed via the Investors section of the Co

– Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of DURAVYU for DME met primary and secondary endpoints – – $371 million of cash and investments on December 31, 2024, providing cash runway into 2027 beyond topline DURAVYU Phase 3 wet AMD data expected in 2026 – WATERTOWN, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the f

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 5, 2025 to report its fourth quarter and full-year 2024 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI804e9c71d61543cab2c16376caae4936. A live audio webcast of the event can be accessed via the Investors section of t

- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a 24-week gain of +7.1 letters and anatomical improvement of 76 microns reduction in CST paired with reduction in treatment burden of two-thirds – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs – – Phase 3 non-inferiority pivotal program initiation anticipated by the end of 2025 – – Conference call to be held today, February 5, 2025 at 8:00 a.m. ET – WATERTOWN, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmac

– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD reinforces potential as a sustained six-month maintenance therapy – – Phase 2 trial of DURAVYU in diabetic macular edema (DME) fully enrolled – – EyePoint to webcast its R&D Day event today at 8:00 a.m. ET – WATERTOWN, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to

WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R&D Day on Wednesday, June 26, 2024 from 8:00 a.m. to 9:30 a.m. ET. The R&D Day will feature presentations and a roundtable discussion from key opinion leader (KOL) guest speakers Carl D. Regillo, M.D., FACS, Professor of Ophthalmology at Thomas Jefferson University, Chief of Retina Service at Wills Eye Hospital, Founder of Wills Eye Clinical Retina Research Unit in Philadelphia, and Partner at

– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to demonstrate favorable safety and tolerability profile with no drug-related serious adverse events – – Conference call to discuss the results to be held at 8:00 a.m. ET – WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced topline results of its Phase 2 PAVIA clinical trial evaluating DURAVYU™ (vorolanib intravitreal insert), previously known as EYP-1901, in pati

WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) --  EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 7, 2024 to report its fourth quarter and full-year 2023 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI91be5d0e320646e887cf4047c70fe73c. A live audio webcast of the event can be accessed via the Investors section of the Company

– Both EYP-1901 cohorts demonstrated a statistically non-inferior change in BCVA versus aflibercept control with a numerical difference of only -0.3 and -0.4 letters, respectively for the 2 mg and 3 mg dose at blended six-month endpoint – – Positive safety profile continues with no EYP-1901-related ocular or systemic SAEs – – Key secondary endpoints were achieved with both EYP-1901 doses. These include an over 80% reduction in treatment burden, with nearly two-thirds of eyes supplement-free up to six-months – – Strong anatomical control in both EYP-1901 cohorts documented by optical coherence tomography (OCT) – – Conference call to discuss the results to be held today, December 4, 2023 a

– Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related ocular or systemic SAEs reported – – Leadership strengthened with the appointment of Stuart Duty to the Board of Directors and the promotion of George Elston to Executive Vice President – – Topline data for Phase 2 DAVIO 2 trial anticipated in December 2023 and Phase 2 PAVIA trial in 2Q 2024 – – Management to host a conference call and webcast today at 8:30 a.m. ET – WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to

WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced it will host a virtual key opinion leader (KOL) event on Thursday, November 9, 2023 from 8:00 to 9:00 am ET. This event will focus on the potential of EYP-1901 in wet age-related macular degeneration (wet AMD), including KOL perspectives on the current wet AMD treatment landscape, vorolanib's unique mechanism of action and outcome considerations for the upcoming topline data read-out for the DAVIO 2 trial in December. The event will be moderate

WATERTOWN, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 1, 2023 to report its third quarter 2023 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI3b701846a11841ad855aab9d0b8aff10. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepo

–Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration remains on track to report topline data in December 2023 – –Phase 2 PAVIA clinical trial evaluating EYP-1901 in non-proliferative diabetic retinopathy remains on track with topline data anticipated in 2Q 2024 – –Jay S. Duker, M.D. promoted to President and Chief Executive Officer – –YUTIQ® franchise sold for $82.5 million cash plus future royalties; all outstanding bank debt retired and cash runway extended into 2025 – –Management to host a conference call and webcast today at 8:30 a.m. ET – WATERTOWN, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a comp

WATERTOWN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 2, 2023 to report its second quarter 2023 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI1f9c401d832f439690f47dc2454e01d6. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.e

– Completed enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration (AMD); topline data anticipated in 4Q 2023 – Enrollment ahead of schedule in the Phase 2 PAVIA clinical trial evaluating EYP-1901 in non-proliferative diabetic retinopathy (NPDR); trial size reduced based on robust body of clinical evidence and proof-of-concept for vorolanib and EYP-1901 – YUTIQ net product revenue increased 60% to $7.4 million compared with $4.6 million in 1Q 2022 – Management to host a conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.

WATERTOWN, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 3, 2023 to report its first quarter 2023 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI90ffc1666dc94fd1b3705e1b5ec9157d. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyep

– Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023 – – Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy (NPDR) on track with enrollment completion anticipated in 4Q 2023 – – Net product revenues for Full Year 2022 of $39.9 million, a 13.0% increase versus Full Year 2021 of $35.3 million – – $144.6M of cash and investments at December 31, 2022 with cash runway projected into 2H 2024 – – Management to host a conference call and webcast today at 8:30 a.m. ET – WATERTOWN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializi

WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full-year 2022 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI25f5945035ff443db085313b1dcde731. A live audio webcast of the event can be accessed via the Investors section

– Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and Phase 2 PAVIA clinical trial for non-proliferative diabetic retinopathy (NPDR) – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at American Society of Retina Specialists (ASRS) 2022 Annual Meeting and American Academy of Ophthalmology (AAO) 2022 Annual Meeting – – Net product revenue of $9.7 million in Q3 2022; a 13% increase from Q3 2021 – – Management to host a conference call and webcast today at 8:30 a.m. ET – WATERTOWN, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmace

WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 2, 2022 to report its third quarter 2022 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/nb4wzrzt. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointphar

– First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at American Society of Retina Specialists (ASRS) 2022 Annual Meeting – – Announced in conjunction with OcuMension Therapeutics, approval of New Drug Application by China's National Medical Products Administration (NMPA) for YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye – – Net product revenue of $11.3 million in Q2 2022; a 30% increase from Q2 2021 – – Management to host a conference call and webcast today

WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 3, 2022 to report its second quarter 2022 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register.vevent.com/. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast

– Presented positive eight-month safety and efficacy data from ongoing DAVIO Phase 1 clinical trial for EYP-1901 in wet age-related macular degeneration (wet AMD) at Angiogenesis, Exudation, and Degeneration 2022; Phase 2 clinical trial expected to initiate in Q3 2022 – – Phase 2 clinical trial for EYP-1901 in non-proliferative diabetic retinopathy (NPDR) expected to initiate in 2H 2022 – – Announced EYP-1901 license to Betta Pharmaceuticals, to develop and commercialize EYP-1901 in China, Hong Kong, Macau and Taiwan; EyePoint retains all rights for EYP-1901 in the rest of the world and expands its exclusive rights to local delivery of vorolanib for the treatment of all ophthalmic diseases

WATERTOWN, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 4, 2022 to report its first quarter 2022 financial results and highlight recent corporate developments. To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 9257913. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.ey

WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and highlight recent corporate developments. To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 5058194. A live audio webcast of the event can be accessed via the Investors section of the Company we

WATERTOWN, Mass., Nov. 13, 2021 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced six-month interim data from the "Durasert® and Vorolanib in Ophthalmology" (DAVIO) Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting wet age-related macular degeneration (wet AMD). The data are being presented today at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting Retina Subspecialty Day in New Orleans by David S. Boyer, M.

WATERTOWN, Mass., Nov. 13, 2021 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced six-month interim data from the "Durasert® and Vorolanib in Ophthalmology" (DAVIO) Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting wet age-related macular degeneration (wet AMD). The data are being presented today at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting Retina Subspecialty Day in New Orleans by David S. Boyer, M.

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that management will host a conference call to highlight interim data from its ongoing Phase 1 DAVIO trial of EYP-1901 for the potential treatment of wet AMD on Saturday, November 13 at 12:00 P.M. ET/11:00 A.M. CST. Dr. Carl Regillo, KOL and Chair of the Company's Scientific Advisory Board, will be participating in the live event. The call will review the interim Phase 1 DAVIO trial results presented by Dr. David Boyer at the late-bre

– Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists (ASRS) – – Topline data for DAVIO trial to be presented at American Academy of Ophthalmology (AAO) 2021 Annual Meeting on November 13, 2021 - – Net product revenues of $8.6 million versus $5.8 million in Q3 2020, a 49% increase – – Management to host a conference call and webcast today at 8:30 AM ET – WATERTOWN, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the li

WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 3, 2021 to report its third quarter 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 9396615. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eye

Positive 30-Day Safety Data Reported for EYP-1901 DAVIO study for the potential treatment of wet AMD; study remains on track for initial readout in Q4 2021 Net product revenues of $8.7 million versus $3.7 million in Q2 2020, a 136% increase;  Management to host a conference call and webcast today at 8:30 AM ET WATERTOWN, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced financial results for the second quarter ended June 30, 2021 and highlighted recent corporate developments. "We made sig

WATERTOWN, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 4, 2021 to report its second quarter 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (877)-312-7507 (domestic) or (631)-813-4828 (international) and reference conference ID 1861354. A live audio webcast of the event can be accessed via the Investors section of the Company website at w